We congratulate Professor Kendall on his recent move to the Australian National University (ANU). 

Please direct any enquiries for Professor Kendall to the ANU. 

Professor Mark Kendall specialises in Targeting the skin for needle-free, minimally invasive vaccine delivery and diagnostics for disease. 

Professor Mark Kendall is a world-leading innovator in producing technology solutions to global health problems; and a translator of commercial technologies focusing on delivery of drugs to skin and skin-based disease diagnostics.  Professor Kendall set himself the research and innovation challenge of asking the world to rethink the role of the needle and syringe as a method of both introducing vaccines to the body and extracting biological material.  He is the inventor of the patented Nanopatch technology, which has many advantages over the more than 160-year-old hypodermic needle.  The Nanopatch could level the global playing field in health, providing safe vaccinations to the developing world, potentially overcoming many of the challenges of the traditional needle as the design technology targets the immune-rich cells of the skin’s out layers (the epidermis and upper dermis) with an array of thousands of micro projections on a single patch. With vaccines dry-coated to the patch, this eliminates the need for vaccine cold chain and removes the need for electricity networks which are so often unreliable in developing countries. Through his research, Professor Kendall has shown the Nanopatch generates equivalent and protective immune responses as the traditional needle, but only needs to deliver a small fraction of the dose (eg 1/100th) making this patch significantly cheaper and easy to apply.

Professor Kendall is a Rolex Laureate, recognising pioneering efforts to expand knowledge and improve human life. He is the recipient of many prestigious accolades, including The Australian Innovation Challenge in 2011. His AIBN group received the 2011 Eureka Prize for Interdisciplinary Research; and the Queensland Clinical Trial Network and Merck’s 2010 Translational Research Excellence Commercialisation Award. Professor Kendall won the Australian Society for Medical Research and Amgen’s Australia Medical Researcher Award in 2008; and was named Young Engineer of Britain 2004. He has presented at more than 90 international seminars and conferences, including the plenary at the 9th Symposium of the Lohmann Therapie-Systeme Academy (LTS) in Germany in 2012. Professor Kendall’s research group received the Eureka Prize for Research by an Interdisciplinary Team in 2011. Professor Kendall is an inaugural Australian Research Council Future Fellow. He has a patent pool of over 130 patents, of which 65 have been granted.  Professor Kendall edits papers in the Journal of Nanotechnology and Shock Waves Journal. .

Industry Engagement & Collaborations

  • Nanopatch technology has been licensed to US –based pharmaceutical company Merck & Co.
  • Instrumental in building up PowderJect/PowderMed, which was sold to Pfizer for $US400million.

Professor Kendall has key international links spanning academia and industry including the University of Oxford, where he was a lecturer; Harvard; PATH; WHO; and the University of Washington. Professor Kendall is a member of a Scientific Advisory Group sponsored by the WHO that aims to fast−track the development of needle−free vaccine delivery technology for use in poor countries. Professor Kendall has lectured at the University of Oxford.

Key Publications

Yeow B, Coffey JW, Muller DA, Grøndahl L, Kendall MAF, Corrie SR. (2013) Surface modification and characterization of polycarbonate microdevices for capture of circulating biomarkers, both in vitro and in vivo. Analytical Chemistry 85(21), 10196-10204.

Coffey JW, Corrie SR, Kendall MAF. (2013) Early circulating biomarker detection using a wearable microprojection array skin patch. Biomaterials 34(37), 9572-9583.

Pearson F, McNeilly CL, Crichton ML, Primiero CA, Yukiko SR, Fernando GJP, Chen X, Gilbert SC, Hill AVS, Kendall MAF. (2013) Dry-coated live viral vector vaccines delivered by Nanopatch microprojectsion retain long-term thermostability and induce transgene-specific T cell responses in mice. PLoS One 8(7), e67888.

Meliga SC, Flaim C, Veidt M, Kendall MAF. (2013) The mechanical stress caused by micro-projection arrays penetrating the skin for vaccine delivery.Australian Journal of Multi-Disciplinary Engineering 10(2), 173-184.

Raphael AP, Meliga SC, Chen X, Fernando GJP, Flaim C, Kendall MAF. (2013) Depth-resolved characterization of diffusion properties within and across minimally-perturbed skin layers. The Journal of Controlled Release 166(2), 87-94.

Crichton ML, Chen X, Huang H, Kendall MAF. (2013) Elastic modulus and viscoelastic properties of full thickness skin characterised at micro scales.Biomaterials 34(8), 2087-2097.

Full list of publications available at UQ eSpace


Since 2001 Professor Kendall has received more than $60 million in competitive research funding and another $65 million from industry.